MXPA05011760A - Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes. - Google Patents

Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes.

Info

Publication number
MXPA05011760A
MXPA05011760A MXPA05011760A MXPA05011760A MXPA05011760A MX PA05011760 A MXPA05011760 A MX PA05011760A MX PA05011760 A MXPA05011760 A MX PA05011760A MX PA05011760 A MXPA05011760 A MX PA05011760A MX PA05011760 A MXPA05011760 A MX PA05011760A
Authority
MX
Mexico
Prior art keywords
angiotensin
progression
diabetes
development
receptor blockers
Prior art date
Application number
MXPA05011760A
Other languages
Spanish (es)
Inventor
Shoichi Yamagishi
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MXPA05011760A publication Critical patent/MXPA05011760A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the field of inhibitors of angiotensin II receptor blockers and particularly addresses their use in diabetes to prevent the development or progression of microvascular disease (i.e. disease involving small blood vessels) affecting eyes (diabetic retinopathy) and kidneys (diabetic nephropathy).
MXPA05011760A 2003-05-02 2004-04-30 Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes. MXPA05011760A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10319592A DE10319592A1 (en) 2003-05-02 2003-05-02 Treatment of diabetic retinopathy with angiotensin II receptor blockers
PCT/EP2004/004616 WO2004096211A1 (en) 2003-05-02 2004-04-30 Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes

Publications (1)

Publication Number Publication Date
MXPA05011760A true MXPA05011760A (en) 2006-01-26

Family

ID=33305091

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011760A MXPA05011760A (en) 2003-05-02 2004-04-30 Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes.

Country Status (12)

Country Link
EP (1) EP1622607A1 (en)
JP (1) JP2006525269A (en)
KR (1) KR20060009288A (en)
CN (1) CN1784225A (en)
AU (1) AU2004233597A1 (en)
BR (1) BRPI0409853A (en)
CA (1) CA2524248A1 (en)
DE (1) DE10319592A1 (en)
MX (1) MXPA05011760A (en)
RU (1) RU2005137361A (en)
WO (1) WO2004096211A1 (en)
ZA (1) ZA200508263B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812770B2 (en) 2006-08-29 2010-10-12 Research In Motion Limited Mobile wireless communications device including an electrically conductive, electrically floating element and related methods
WO2009087900A1 (en) * 2008-01-11 2009-07-16 Daiichi Sankyo Company, Limited Pharmaceutical agent for prevention or treatment of diseases accompanied by intraocular vascular hyperpermeability
JP5860210B2 (en) * 2010-12-07 2016-02-16 株式会社オフテクス Composition for promoting lacrimal secretion containing at least one of telmisartan and losartan, an angiotensin II receptor antagonist, and a preparation for oral administration containing lacrimal secretion containing the composition
KR102233673B1 (en) * 2016-01-27 2021-03-30 보령제약 주식회사 Pharmaceutical composition for preventing or treating diabetic nephropathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (en) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
EP1312379A4 (en) * 2000-08-25 2004-08-25 Takeda Chemical Industries Ltd Fibrinogen lowering agents
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt

Also Published As

Publication number Publication date
CA2524248A1 (en) 2004-11-11
AU2004233597A1 (en) 2004-11-11
CN1784225A (en) 2006-06-07
BRPI0409853A (en) 2006-05-16
RU2005137361A (en) 2006-07-27
KR20060009288A (en) 2006-01-31
ZA200508263B (en) 2007-02-28
DE10319592A1 (en) 2004-11-18
WO2004096211A1 (en) 2004-11-11
EP1622607A1 (en) 2006-02-08
JP2006525269A (en) 2006-11-09

Similar Documents

Publication Publication Date Title
Rüster et al. Renin-angiotensin-aldosterone system and progression of renal disease
EA200802184A1 (en) PHARMACEUTICAL COMPOSITIONS WITH DPP IV INHIBITORS
EA200701845A1 (en) ROFLUMILAST FOR TREATMENT OF DIABETES MELLITUS
EA200701159A1 (en) COMBINED MEDICINE INCLUDING TELMISARTAN AND HYDROCHLORTHIAZIDE
AR052082A1 (en) COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH THE INCREASE OF THE SANGUINEA CONCENTRATION OF GELP -1
CL2007000601A1 (en) Compounds derived from pyrazolic heterobicycles, inhibitors of thyroxine kinase protein activity; pharmaceutical composition comprising said compounds; and use of the compounds in the treatment of a hyperproliferative disease.
EA200971131A1 (en) BIOMARKERS FOR PREDICTING SENSITIVITY OR NO SENSITIVITY TO ANTI-TNF AGENTS
EA201300583A1 (en) VASOPROTECTIVE AND CARDIOPROTECTIVE ANTI-DIABETIC TREATMENT
NO20091413L (en) WNT antagonists and their use in the diagnosis and treatment of WNT-mediated disorders
UA88257C2 (en) Use of protein kinase c alpha inhibitor for the treatment of renal diseases involving proteinuria and diabetic nephropathy, retinopathy or neuropathy
EA200800762A1 (en) PREVENTION OF HYPOTENCY AND STABILIZATION OF BLOOD PRESSURE IN HEMODIALYSIS PATIENTS
MX2008002370A (en) Exendin for treating diabetes and reducing body weight.
DOP2009000269A (en) HUMANIZED ANTIBODIES AGAINST GLOBULOMERO AB (20-42) AND ITS USES
NO20062088L (en) Pharmaceutical preparation comprising a selective I1-imidazoline receptor agonist and an angiotensin II receptor blocker
DK2026803T3 (en) Compositions of R (+) and S (-) pramipexole and methods for their use
EA200500218A1 (en) TREATMENT OF KIDNEY INSUFFICIENCY WITH THE USE OF INTERFERON-β
ATE515504T1 (en) SUBSTITUTED IMIDAZOLE-4-CARBOXAMIDE AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS
CY1112184T1 (en) PYRIDOXAMINE FOR USE IN TREATMENT OF DIABETIC Nephropathy in Type II Diabetes
MA28507B1 (en) OPHTHALMIC SOLUTION COMPRISING SODIUM CARBOXYMETHYLECELLULOSE AND HYDROXYPROPYLMETHYLOCELLULOSE
ATE473004T1 (en) SUBSTITUTED IMIDAZOLE-4-CARBOXAMIDE AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS
NO20082345L (en) Selective VPAC2 receptor peptide agonists
ATE479435T1 (en) SUBSTITUTED IMIDAZOLE-4-CARBOXAMIDE AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS
Chawla et al. Gap between evidence and patient access: policy implications for bariatric and metabolic surgery in the treatment of obesity and its complications
MXPA05011760A (en) Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes.
Park et al. Restoration of erectile capacity in normotensive aged rats by modulation of angiotensin receptor type 1